Dupilumab in Atopic Dermatitis: Skin of Color Findings
- New research presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress suggests dupilumab monotherapy effectively improves multiple skin measures in patients with skin of color...
- Oren Markowitz presented findings at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, France (September 17-20, 2025).
- This is notably significant given past underrepresentation of diverse skin types in clinical trials for atopic dermatitis treatments.
“`html
Dupilumab Shows Promise for Atopic dermatitis in Skin of Color, Study Finds
Table of Contents
New research presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress suggests dupilumab monotherapy effectively improves multiple skin measures in patients with skin of color suffering from atopic dermatitis.
what Happened?
Researchers led by Dr. Oren Markowitz presented findings at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, France (September 17-20, 2025). The study utilized Line-Field Optical Coherence Tomography (LF-OCT) to assess the impact of dupilumab monotherapy on skin measures in patients with skin of color diagnosed with atopic dermatitis. LF-OCT is a non-invasive imaging technique that allows for detailed visualization of skin structure.
The research team, including N. Shiao and B. Shumel, found improvements in multiple skin measures. This is notably significant given past underrepresentation of diverse skin types in clinical trials for atopic dermatitis treatments.
Why This Matters: Addressing Depiction in Dermatology
Atopic dermatitis affects a diverse patient population globally. However,clinical trials often lack proportional representation of different ethnicities and skin types. This can lead to uncertainty about how well treatments perform across all groups.
Dr. Markowitz highlighted this issue,stating,“I think that there are certain skin types and ethnicities that tend to be underrepresented in studies compared to the incidence of disease at large. Clearly,inflammatory issues such as atopic dermatitis have a very diverse patient population when we look at incidents in the United States and throughout the world. And when you look at the percentage of these patients in the clinical trials, it’s limited, so getting very clear data on what we saw demonstrates that it’s very similar in diverse skin types, as it is, in terms of the medication’s efficacy and side effect profile, which is very good.”
The study builds on previous subgroup analyses of Phase 3 dupilumab data,which,despite limited sample sizes,indicated a comparable risk-benefit profile in patients with skin of color to the overall atopic dermatitis population.
Dupilumab: A Deeper Look
Dupilumab is a biologic medication that targets specific proteins involved in inflammation. It’s approved for the treatment of moderate-to-severe atopic dermatitis in adults and children. It works by blocking the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13), key drivers of the inflammatory response in atopic dermatitis.
The use of LF-OCT in this study provides a more detailed understanding of how dupilumab impacts skin structure at a microscopic level in patients with skin of color. This is a valuable addition to the existing body of evidence supporting the drug’s efficacy.
Line-Field Optical Coherence Tomography (LF-OCT): A Technical Overview
LF-OCT is a non-invasive imaging technique that provides high-resolution, cross-sectional